Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc. is a biotechnology company listed on the NASDAQ under the ticker ANIX. The company focuses on developing therapies and vaccines aimed at unmet needs in oncology. Its therapeutics work includes liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy and a form of CAR-T technology being developed for ovarian cancer. Anixa is also advancing a breast cancer vaccine program and a broader vaccine discovery effort intended to support the development of additional cancer vaccines for difficult-to-treat malignancies, including cancers of the lung, colon, and prostate. The company was previously known as ITUS Corporation and adopted its current name in October 2018. Incorporated in 1982, Anixa Biosciences is based in San Jose, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ANIX
|
$2.43
|
-33.0% Downside
|
Overvalued
|
$10
|
176.2% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
September 11, 2026
|
-12.1x
|
8.4x
|
—
|
117.7 M
|
107 M
|
0.2%
|
94.6%
|
17.6
|
—
|
70.9%
|
